The FDA has moved to speed review timelines for three psychedelic-focused programs using national priority commissioner vouchers tied to mental health indications. The agency’s fast-track approach targets a psilocybin treatment for treatment-resistant depression from Compass Pathways, a similar psilocybin program from the Usona Institute for major depressive disorder, and an MDMA-like candidate from Transcend Therapeutics for post-traumatic stress disorder. The voucher mechanism can change review duration and review resource allocation for qualifying candidates, and the FDA’s decision is arriving amid broader political attention on psychedelics in the U.S. mental health pipeline. Separate reporting indicates the FDA’s voucher recipients were framed as a “surprise” to some market participants, highlighting how regulatory process decisions can rapidly shift perceived development momentum for psychedelics developers.